Connect with us

CBD

Scientists Studying Cannabis Now Have Access To More Plants For Their Research : Shots

Published

on

More than 30 states have medical marijuana programs – but scientists are only allowed to use cannabis plants from a U.S. source for their research. That will change as the federal government starts adding more growers to the mix. Drew Angerer / Getty Images hide subtitles

Toggle labeling

Drew Angerer / Getty Images

More than 30 states have medical marijuana programs – but scientists are only allowed to use cannabis plants from a U.S. source for their research. That will change as the federal government starts adding more growers to the mix.

Drew Angerer / Getty Images

After more than 50 years, the federal government is lifting a roadblock to cannabis research that scientists and proponents believe has hampered rigorous studies of the plant and possible drug development.

Since 1968, US researchers have only been allowed to use cannabis from a domestic source: a facility at the University of Mississippi under a contract with the National Institute on Drug Abuse (NIDA).

That changed earlier this month when the Drug Enforcement Administration announced that several more American companies are currently being registered to manufacture cannabis for medical and scientific purposes.

It’s a move that promises to accelerate understanding of the plant’s health effects and possible therapies to treat conditions – chronic pain, chemotherapy side effects, multiple sclerosis, and mental illness, among others – that have yet to be well researched.

How a boy's battle with epilepsy led to the first marijuana-derived medicine

“This is an important decision,” said Rick Doblin, executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS), which has spearheaded research into other List 1 drugs – the most restrictive class of controlled substances that the federal government “defines” as. Medicines with no currently accepted medical use. “

“This is the final policy barrier to research with List 1 drugs,” he says.

About a third of Americans currently live in a state where recreational marijuana is legal – and more than 30 states have medical marijuana programs. Still, scientists are not allowed to simply use the cannabis sold in state-licensed pharmacies for their clinical research, as cannabis remains illegal under federal law.

Medical Marijuana 'Catch-22': Limitations of Research Hinder Patient Relief

“It’s a big breakup,” says Dr. Igor Grant, professor of psychiatry and director of the Center for Medical Cannabis Research at the University of California at San Diego.

The new DEA decision does not resolve the conflict between federal and state laws, but it does offer researchers a new, federally approved pipeline for more products and strains of cannabis.

“We’re going to see a decade or more of explosive cannabis research and potential new therapies,” says Dr. Steve Groff, founder and chairman of Groff North America, one of three companies that has publicly announced that it has received preliminary approval from the federal government to grow cannabis for research.

A long struggle for the abolition of the federal “monopoly”

Despite their best efforts, scientists have faced administrative and legal hurdles in growing pharmaceutical-grade cannabis for decades.

In 2001, Dr. Lyle Craker, a noted plant biologist, first obtained a license to grow marijuana for research – only to experience years of delays that sparked a lengthy legal battle with the DEA, which must give the green light to Schedule 1 drug research like cannabis.

“There are thousands of different cannabis strains, each with unique chemical profiles and unique clinical effects, but we haven’t had access to this normal variety,” says Dr. Sue Sisley, cannabis researcher and President of the Scottsdale Research Institute also received DEA preliminary approval to manufacture cannabis for research.

It wasn’t until 2016 that the federal government signaled a change in policy that would open the door to new producers, but applications for it lagged behind for years. Craker and others eventually sued the federal government for the delay.

Psychiatrist is studying possible benefits of treating PTSD with ecstasy or cannabis

Sisley has long had problems with the delivery of cannabis from the NIDA facility in Mississippi – especially with the way it’s processed. She used cannabis produced there in their recently published clinical trial for the treatment of PTSD in military veterans.

She describes the product as an “anemic” greenish powder.

“It’s very difficult to overcome the placebo effect when something is diluted,” she says.

The 76-person study, which took 10 years to complete, concluded that smoked cannabis was generally well tolerated and had no harmful effects in this group. However, there was also no statistically significant difference in PTSD symptom relief compared to a placebo.

For Grant of UCSD, the problem with the long-term supply of cannabis is not so much the quality, but the lack of various products such as foods and oils as well as cannabis varieties with different concentrations of CBD and THC, the most important psychoactive component of the plant.

“We don’t have enough research on the types of marijuana products people use in the real world,” he says.

As CBD oils grow in popularity, the FDA is considering setting new rules

Because of the limited domestic supply, some researchers have resorted to importing cannabis from outside the United States – a legal but extremely counterintuitive arrangement that is “arduous” and prone to hiccups, Sisley says.

The restrictions on cannabis research have also hampered the path to drug development, as the NIDA facility’s cannabis could only be used for academic research and not for prescription drug development. A drug that has been studied in phase 3 clinical trials – what is required before it is submitted for approval by the Food and Drug Administration – must match what will later be marketed.

“The NIDA monopoly was primarily why we have medical marijuana in the US, but we don’t have medical marijuana through the FDA,” says Doblin of MAPS. “It is a fundamental change that we can now have drug development with domestic supplies.”

There are still some obstacles

The few companies soon to get DEA cannabis-growing sites have an eager market of researchers “demanding” the opportunity to study the plant’s scientific properties and medicinal potential, says Groff, whose company is responsible for the DEA. Approval is pending and who also has an FDA project investigating the antimicrobial properties of cannabis for killing dangerous bacteria like MRSA.

By the end of next year, Groff expects his company to produce up to 5,000 pounds of marijuana a year to offer researchers a “full menu of customizable options.”

The biopharmaceutical research firm – a third company that will soon grow cannabis with a DEA license – has already made dozen of agreements with U.S. researchers and is hearing from more academic institutions, drug makers, and biotech companies as policy changes, says it the CEO George Hodgin.

“Now there is a very clear, approved, and legal way for them to legally enter the cannabis space in the United States,” says Hodgin.

Washington State University’s Cannabis Policy, Research, and Public Relations Center is one of the places where cannabis is expected to be sourced from Hodgin’s business.

“It’s definitely a big step in the right direction as the industry is moving much faster than we are in research,” said Michael McDonell, associate professor of medicine and director of the university’s cannabis center.

But he also points out that even with more online growers it is by no means easy to study cannabis, as researchers need a special license to work with a List 1 drug and grants to conduct these studies are difficult to come by are.

Despite the widespread use of marijuana in the US, research into the medical potential of other List 1 drugs like MDMA (ecstasy) is much more advanced than cannabis.

According to the UCSD grant, the biggest leap in research would be to remove cannabis from the Schedule 1 drug classification. “If that happened,” he says, “it would solve a lot of the problems we talked about.”

CBD

Revealing Covid-19 impact on CBD Isolate market growth over 2021-2026

Published

on

Uncovering the Impact of Covid-19 on CBD Isolate Market Growth in 2021-2026

Category: #business |
From administrator |
Published: 23 minutes ago

| Product ID: 3878547 |

The main objective of the latest research report on the CBD Isolate Market Size is to predict the performance of the industry for years to come, taking into account competitive dynamics and the regional landscape. In addition, the study highlights key growth drivers and profitable prospects that will increase the compensation latitude of the market in the forecast period 2020-2025. It also identifies barriers to industry growth as well as strategies to mitigate their impact.

Additionally, the Business Intelligence report provides an in-depth assessment of the market segmentation to help investors discover the main areas with high sales potential. It also provides up-to-date information on the Covid-19 pandemic to help stakeholders make effective decision-making for the future.

Main highlights from the COVID-19 impact analysis:

  • Effects of Covid-19 on society and the economy
  • Effects of the pandemic on market development
  • Interventions in the supply and demand chain

Request a sample copy of this report @ https://www.business-newsupdate.com/request-sample/161691

Overview of the regional landscape:

  • The major regional contributions to the CBD Isolates market are North America, Europe, Asia-Pacific, the Middle East, and Africa and South America.
  • The contribution of each region to the growth of the overall market is thoroughly analyzed in the report.
  • Key features such as pricing patterns, returns, total sales, and growth rate forecasts for each region are included in the report.

More Highlights from the CBD Isolate Market Report:

  • The product range of the CBD Isolate market is in marijuana-derived and hemp-derived.
  • Sales and growth rate estimates are provided for each product type.
  • Details of the market share, growth rate, and production patterns of each product type are described in the report.
  • The scope of the CBD Isolates market is categorized into Cosmetics Industry, Food Industry, Pharmaceutical Industry, Other, Geographic, the detailed analysis of the production and trade of the following countries is covered in Chapter 4.2, 5:, USA, Europe, China, Japan and India.
  • The report provides details of each application’s market share along with its growth rate over the forecast period.
  • Major players in the CBD isolate market are Emblem Cannabis Oils, Cannavest, PharmaHemp, Aphria, Select, CBD American Shaman, Endoca, NuLeaf Naturals, Kazmira, The Lab, Whistler, Absolute Terps, Green Road, HempLife Today, Medical Marihuana, Folium Biosciences , Freedom Leaf, CW Hemp / CW Botanicals, and Canopy Growth Corporation
  • The report cites key information about the products and services produced, as well as the market valuation and production framework of the main players.
  • A thorough analysis of the supply chain, from dealers, distributors, to customers, is provided in an easy-to-understand manner.
  • A comprehensive study of the profitability of a new project is conducted using Porter’s Five Forces Analysis and SWOT assessment tools.

Key questions answered in the report:

What will be the growth rate of the CBD Isolate market?

What are the key factors driving the global CBD isolate market?

Who are the major manufacturers in the CBD isolate market?

What are the Market Opportunities, Market Risk, and Market Overview of the CBD Isolate Market?

What is Sales, Revenue, and Price Analysis from Top Manufacturers in the CBD Isolate Market?

What CBD Isolate Market Opportunities and Threats Are Vendors Facing in the Global CBD Isolate Industry?

What is Sales, Revenue, and Price Analysis by Types and Uses of the CBD Isolate Market?

Request customization for this report @ https://www.business-newsupdate.com/request-for-customization/161691

Continue Reading

CBD

What is the strongest CBD oil I can get?

Published

on

We include products that we believe will be useful to our readers. If you buy from links on this page, we may earn a small commission. Here is our process.

CBD, or cannabidiol, is a chemical compound and one of several cannabinoids found in the cannabis sativa plant. There are many forms of CBD, including oils. Some of the strongest products can contain up to 7,500 mg of CBD per 30 ml.

CBD has become a popular ingredient in oils, edibles, topicals, and even cosmetics. CBD does not cause the “high” typically associated with cannabis use. The cause of the “high” is another cannabinoid called tetrahydrocannabinol (THC).

People interested in CBD products and regular consumers alike may marvel at the strongest CBD oil on the market.

In this article, we provide a list of highly potent CBD oils and other CBD products. We also discuss the potential benefits and risks of using strong CBD.

Confused About CBD? Read our complete buying guide here.

Is CBD Legal?? Hemp-derived CBD products with less than 0.3% THC are legal at the federal level, but are still illegal under some state laws. On the other hand, cannabis-derived CBD products are illegal nationwide, but legal under some state laws. Check local laws, especially when traveling. Also, keep in mind that the Food and Drug Administration (FDA) has not approved any over-the-counter CBD products that may be inaccurately labeled.

Below are some examples of high potency CBD oils and tinctures. Oils and tinctures go through slightly different extraction processes. Manufacturers produce CBD oils using carbon dioxide to extract the CBD, while tinctures undergo a process using alcohol.

Learn more about CBD tinctures here.

Please note that the author of this article has not tried these products and all information presented is research-based. All of the CBD products featured in this article have passed our rigorous review process.

Zaural full spectrum CBD oil drops

Zatural Full Spectrum CBD Oil Drops contain hemp seed oil and essential oils from peppermint, spearmint, coffee, cinnamon and lemon-lime.

The company states that the product is THC-free.

This product is available in 1, 2, and 4 fluid ounces (fl oz) bottles that contain 300–6,000 milligrams (mg) of CBD.

Zaural Full Spectrum CBD Oil Drops can be bought online.

Spruce 2,400 mg laboratory-grade CBD oil

Spruce’s 2,400 mg full-spectrum CBD oil provides 80 mg of full-spectrum CBD per 1 milliliter (ml) dose, which is equivalent to a full pipette.

The oil is organic and does not contain any additional flavors. The carrier oil is hemp seed oil, and the product is vegan and gluten-free.

This product contains 0.3% THC and the company states that a person ingesting it could test positive for cannabis.

Use the code “MNT” for 15% discount and free shipping.

Spruce 2,400 mg laboratory-grade CBD oil is available for purchase online.

NuLeaf Naturals full spectrum hemp CBD oil

NuLeaf Naturals offers a 6,000 mg full spectrum CBD oil. The company extracts the CBD from organic hemp grown in Colorado.

NuLeaf Naturals uses full spectrum CBD and organic hemp seed oil to make their CBD oil products. The product is organic and tasteless.

People can also choose to buy a single bottle or buy packs of 3 or 6 bottles.

NuLeaf Naturals full spectrum hemp CBD oil can be purchased online.

MyNaturalCBD full spectrum CBD oil tincture

This full spectrum CBD oil from MyNatural CBD contains around 167 mg of CBD per ml and around 8.2 mg of CBD per drop.

MyNatural CBD offers CBD oils in strengths of 300, 1,000 and 2,500 mg.

The company states that the product has less than 0.3% THC. contains

MyNaturalCBD full spectrum CBD oil tincture can be bought online.

CBDMD CBD Oil Tincture Drops

CBDMD’s Premium CBD Oil contains 7,500 mg of broad spectrum CBD per 1 fl oz bottle.

It also contains additional cannabinoids, including cannabinol (CBN) and cannabigerol (CBG). This tincture is available in natural, mint, orange or berry flavors.

It’s vegan and gluten free.

The company guarantees this product contains undetectable levels of THC.

Use the code HEALTHLINE for a 20% discount on all orders.

CBDMD CBD tincture drops can be bought online.

Veritas Farms full spectrum CBD tincture

Veritas Farms produces a full spectrum CBD tincture with up to 2,000 mg of CBD per bottle. Like many others, this product is also available in lower strengths.

Veritas Farms also offers its product in five different flavors, including watermelon and strawberry. The flavored versions contain organic stevia and other natural oils. The tasteless version is free from these ingredients.

The company uses organic coconut oil in its products.

Veritas Farms states that the product contains 0.3% THC or less.

Veritas Farms’ full spectrum CBD tincture can be purchased online.

While there is an abundance of research into the effects of cannabis and THC, there are very few high quality human studies examining CBD on its own.

However, new research comes out every day, which means that our knowledge of CBD and its effects is likely to increase significantly in the decades to come.

It is difficult for experts to predict exactly how differences in strength will affect the effectiveness of CBD.

Based on the results of a 2020 review, CBD appears to be relatively safe at various dosages. However, the authors did not set a specific dose or range of doses that they believed would benefit everyone.

Most of the studies included in this review rated daily doses of 300–600 mg of CBD, but some studies reported doses up to 2,000 mg per day.

Everyone reacts differently to CBD, so it’s best for people who are first time using CBD to start on a lower dose.

Buying a product that has a higher concentration of CBD in it can be more cost effective for some people.

Someone using 300 mg of CBD for chronic pain or anxiety would use 12 full droppers of a 25 mg of CBD oil. However, you could get a similar dose of 300 mg using just a drop and a half of a 2,000 mg CBD oil.

While stronger products may deliver more CBD per unit, they can result in inaccurate dosing.

Learn more about CBD dosage here.

According to a 2018 report by the World Health Organization (WHO), even at doses above 150 mg per kilogram (kg) of body weight, CBD does not appear to cause significant side effects.

The Food and Drug Administration FDA warns that using CBD products can cause the following side effects:

  • feeling sleepy
  • Gastrointestinal problems
  • diarrhea
  • decreased appetite
  • Mood changes such as irritability
  • Liver damage (certain drug interactions)
  • Interactions with alcohol and other drugs

The FDA has only approved one CBD product called Epidiolex for severe forms of epilepsy in children. The FDA doesn’t regulate other CBD products.

Learn more about the side effects of CBD here.

In a 2017 study, researchers rated the label accuracy of 54 CBD products from 31 companies. They tested a range of products, including oils, tinctures, and steam formulas. Their third-party laboratory analysis showed that only 30.95% of the products had specified concentrations of CBD.

According to the authors, CBD oils had more accurate labeling than tinctures and steam formulas.

Most reputable CBD manufacturers, however, will provide third-party laboratory results to their customers.

Consumers should always be careful when buying CBD, especially high potency products. Highly effective CBD products can be inaccurately labeled. Some products may not even contain CBD.

Some CBD products can contain enough THC to give a positive result on a drug test.

Learn more about THC and drug testing here.

CBD is a popular ingredient in consumer products. Current preliminary research suggests that CBD may prove beneficial in treating a number of conditions, including epilepsy, anxiety, and other mood disorders, as well as some forms of chronic pain.

Learn more about the potential benefits of CBD oil here.

However, higher quality, controlled studies are needed to validate the medical uses of CBD.

People who currently use CBD products but think they could benefit from more powerful alternatives can use this article for guidance. People who have never used CBD but are interested in giving it a try should start with a lower dose and gradually work their way up to stronger products.

People should also discuss CBD with a doctor or health care provider before taking it, as it can interact with other medications a person is taking.

Learn more about cannabinoids and possible drug interactions here.

Continue Reading

CBD

Canna-entrepreneur Mandy Froelich tells how cannabis legalization and new leadership will transform South Dakota — The South Dakota Standard

Published

on

Growing up in Spearfish, I attended many DARE demonstrations and meeting talks at school. The fear-based campaigns turned out to be working. I didn’t touch cannabis until I was 19 years old and lived overseas in Costa Rica.

However, once I tried it, I quickly realized that the possible negative effects were drastically exaggerated by the mainstream media and members of society. As a Registered Holistic Nutritionist (RHN), cook, and journalist, it became my mission to share science-based insights and personal anecdotes from activists who have experienced cannabis-related relief.

Of course, my husband (a cannabis gardener) and I became entrepreneurs in the industry and started the education center, My Stoned Kitchen. With legalization in sight (as pictured above from leafly.com), we are now about to return to South Dakota. However, we are also preparing for the inevitable pushback – from both citizens and Governor Kristi Noem.

As a canna entrepreneur with five years of industry experience in Colorado and Las Vegas, my husband and I are not naive enough to believe that Noem is really a supporter of cannabis legalization or the much-needed boost to the state’s economy. It is for this reason that I share my opinion on the need to adopt herbal medicine and call for fair, respectable and honest leadership in 2022.

My favorite part of teaching people how to make food and herbs their medicine is watching the moment when relief finally sets in. For example, many older people suffer from physical pain and have no appetite. After nibbling on a 10 milligram biscuit made from almond flour, eggs, and honey, they often chat up a storm and rave about how good they are feeling.

I’ve also seen young children with epilepsy go from six seizures a day to two in six months. The quality of their lives and that of their families from ingesting full-spectrum cannabis oil is miraculous to say the least. In addition, everyday cannabis use can drastically reduce anxiety, depression, and feelings of separation in adults over 21. I am one of those people and it is frankly a medicine I use a lot to keep my own mental health in check.

The benefits of cannabis go beyond consuming the THC and CBD components, which are primarily derived from marijuana. Hemp is also a by-product of growing cannabis and has thousands of uses. In addition to being used to make paper, industrial materials, and clothing, the fibrous plant is also used in the health food world as a dietary supplement for omega-3 fatty acids and proteins.

For these reasons, there is a clear demand for the crop. Since South Dakota is an agriculturally producing state, one would think that this lucrative raw material would be welcomed with open arms. However, Governor Noem has repeatedly denied permission in South Dakota. In my opinion, this lack of foresight is a farce and shows a lack of integrity and consideration for people.

Marijuana sales tax revenues continue to break records in neighboring states like Colorado. 2020, for example, resulted in a new high of over $ 2 billion in state taxes.

According to the Marijuana Movement, 65% of total revenue comes from the state’s 15% retail excise tax. The funds raised through medical and recreational stoner activities are allocated to local governments and state education, transportation and marijuana tax funds.

How could this income flood affect South Dakota, where 14.6% of the state’s population lives in poverty? With sufficient resources for schools and the teachers they employ, how could education be improved? Would the legalization of recreational cannabis bring life to small family businesses? If only South Dakota had a guide to find out.

If Noem were really interested in improving the state, she would recognize the people’s choice to give access to this drug. South Dakota’s new cannabis website suggests that it is an ally for the cause. But history cannot be rewritten.

After the November election, in which South Dakota voters approved Measure 26, Noem wrote a letter to the legislature asking them to block portions of the new law on July 1st. She said in March, “I still think it’s a bad idea for our state,” AP reported.

Let’s not forget that Noem also used taxpayers money to lead their fight against Voter-approved Amendment A. As the TV commercial “Money” (which was played during Noem’s gubernatorial campaign in 2018) shows, there are numerous points of corruption in Noem’s career.

Noem took nearly $ 3 million from Special Interests.

Noem used a loophole to pour $ 1.6 million in overseas money into their campaign for governorship … just a week after the South Dakotans voted to make it illegal.

Your campaign team was fined by the Republican Secretary of State for violating campaign finance.

Like other South Dakota locals who lived in fear of criminalization, my husband and I went to learn more about and work in the cannabis field. We will be returning shortly to be closer to family and help build this much needed industry. Despite the inevitable challenges, I am excited to see what this state will choose for itself. South Dakota is on the brink of great change and could harvest a harvest that has the potential to heal people, stimulate the economy, and support the longevity of family businesses. Why shouldn’t we want that?

The realization is that the people of South Dakota deserve a vote. With better education and support for community integration, this state could thrive. I will continue to work towards this vision and hope to meet many more residents with this attitude. Enough is enough, don’t you think?

Mandy Froelich is a neurodivergent entrepreneur who works in a wide variety of industries. As a consultant, entrepreneur, and author, she teaches people how to create financial, physical, and spiritual wellbeing. Froelich is the co-founder of My Stoned Kitchen, a free online hub to learn how to grow organic cannabis and make healthy edibles. At Life in Bloom Nutrition, she also teaches the principle of making food your medicine. Connect with her below www.MandyFroelich.com.

Continue Reading
Advertisement

Trending